An interventional study of Biodesign™ SIS graft and Doyle silastic sheet in Nasal Septum Perforation, sponsored by University of Alabama at Birmingham. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to demonstrate the utility of porcine small intestinal submucosa (SIS) as a graft material that may aid in the natural healing process of freshly exposed bone and cartilage in the nasal cavity.
Patients who undergo endoscopic endonasal skull base surgery, and may require nasoseptal flap placement as part of skull base reconstruction, will be informed, consented and enrolled for participation. If the intraoperative decision is ultimately made for harvest and placement of full-length nasoseptal flap by each individual surgeon, patients will then be consecutively, sequentially randomized to use of either:
When used, Biodesign graft will be soaked in sterile saline out of the packaging, and placed as an intact single sheet over the exposed bone nasal septum bone/cartilage (without trimming). For uniformity and ease of future analysis, the bottom edge of the graft will be placed parallel to, and proximal to, the nasal floor cut edge remnant mucosal surface as possible. Except for a thin Doyle silastic sheet to cover the graft site, no additional reinforcement (suture/tissue glue) will be placed for those patients in the Biodesign graft arm.
Time Points and Study Parameters:
All patients will be assessed at 2 weeks, 6 weeks and 12 weeks following randomization and entry into this study.
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
Other: Biodesign™ SIS graft · Other: Doyle silastic sheet
Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
Other: Doyle silastic sheet
2x3 cm Biodesign™ SIS perforated mesentery graft
Doyle silastic sheet
Mean Change in Post-operative Remucosalization at the Donor Site
Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative remucosalization is a Likert scale ranging from 0% (no remucosalization) to 100% (complete remucosalization), with higher scores representing better healing.
Time frame: 2 weeks, 6 weeks, 12 weeks
Mean Change in Post-operative Locoregional Crusting at Donor Site
Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative crusting is a Likert scale ranging from 0 (no crusting) to 10 (complete crusting), with lower scores representing better healing.
Time frame: 2 weeks, 6 weeks, 12 weeks
Mean Change in Post-operative Edema at the Donor Site
Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative edema is a Likert scale ranging from 0 (no edema) to 10 (severe edema), with lower scores representing better healing.
Time frame: 2 weeks, 6 weeks, 12 weeks
| Milestone | Treatment Group | Control Group |
|---|---|---|
| Started | 21 | 26 |
| Completed | 21 | 25 |
| Not completed | 0 | 1 |
Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative remucosalization is a Likert scale ranging from 0% (no remucosalization) to 100% (complete remucosalization), with higher scores representing better healing.
| percentage of remucosalization | Treatment Group | Control Group |
|---|---|---|
| 2 weeks | 47.8 (40.3 to 55.3) | 37.8 (31.1 to 44.5) |
| 6 weeks | 49.7 (41.6 to 57.8) | 43.5 (36.7 to 50.3) |
| 12 weeks | 73.9 (63.8 to 83.9) | 65.3 (56.97 to 73.7) |
| overall change | 57.1 (52.1 to 62.2) | 48.9 (45.1 to 52.7) |
Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative crusting is a Likert scale ranging from 0 (no crusting) to 10 (complete crusting), with lower scores representing better healing.
| score on a scale | Treatment Group | Control Group |
|---|---|---|
| 2 weeks | 3.50 (2.99 to 4.01) | 4.22 (3.50 to 4.94) |
| 6 weeks | 4.22 (3.03 to 5.41) | 5.2 (4.17 to 6.24) |
| 12 weeks | 2.64 (1.48 to 3.80) | 2.92 (2.17 to 3.66) |
| overall change | 3.45 (2.97 to 3.93) | 4.11 (3.63 to 4.59) |
Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative edema is a Likert scale ranging from 0 (no edema) to 10 (severe edema), with lower scores representing better healing.
| score on a scale | Treatment Group | Control Group |
|---|---|---|
| 2 weeks | 3.34 (2.94 to 3.75) | 3.52 (3.16 to 3.89) |
| 6 weeks | 3.25 (2.74 to 3.76) | 3.15 (2.75 to 3.55) |
| 12 weeks | 2.26 (1.84 to 2.70) | 2.65 (2.11 to 3.19) |
| overall change | 2.95 (2.73 to 3.18) | 3.11 (2.86 to 3.35) |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Group | 0/21 (0%) | 0/21 (0%) | 7/21 (33.3%) |
| Control Group | 0/26 (0%) | 0/26 (0%) | 8/26 (30.8%) |
| Event | Treatment Group | Control Group |
|---|---|---|
| minor septal perforationSkin and subcutaneous tissue disorders | 4/21 | 6/26 |
| development of transverse synechiae between septum and inferior turbinateSkin and subcutaneous tissue disorders | 3/21 | 2/26 |
| Age, Categorical(Participants) | Treatment Group | Control Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 16 | 23 | 39 |
| >=65 years | 5 | 3 | 8 |
| Sex: Female, Male(Participants) | Treatment Group | Control Group | Total |
|---|---|---|---|
| Female | 15 | 15 | 30 |
| Male | 6 | 11 | 17 |
| Race (NIH/OMB)(Participants) | Treatment Group | Control Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 7 | 11 |
| White | 10 | 8 | 18 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 10 | 17 |
No study locations are listed for this record.
Plan to share: No
Ran from Nov 2014 to primary completion in Mar 2016, 16 months.
Results were first posted in Sep 2019, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nasal Septal Perforation
University of Alabama at Birmingham →